<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4"><strong>Brucella</strong></h1><h2 class="text-xl font-semibold mt-6 mb-3"><strong>1. Definition, Taxonomy &amp; Classification</strong></h2><ul><li><strong>Brucellosis</strong> (aka Malta, Crimean, Mediterranean, Rock, undulant, Bang’s disease).</li><li>Caused by <em>Brucella</em> spp.: small, <strong>Gram-negative coccobacilli</strong>, <strong>facultative intracellular pathogens</strong> (within macrophages/reticuloendothelial system).</li><li>non-motile, non-spore-forming, aerobic.</li><li><em>B. abortus</em> and <em>B. suis</em> may require 5–10% CO₂.</li><li>Do not ferment sugars.</li><li><strong>Closely related</strong> to <em>Bartonella</em></li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Human pathogenic species:</strong></h3><ul><li><em>B. melitensis</em>: goats, sheep, camels – <strong>most virulent, most common worldwide</strong>, acute presentation.</li><li><em>B. abortus</em>: cattle.</li><li><em>B. suis</em>: pigs, hares, reindeer.</li><li><em>B. canis</em>: dogs (milder human disease).</li><li>Rare: <em>B. ceti</em>, <em>B. pinnipedialis</em> (marine mammals), <em>B. inopinata</em> (human isolate, e.g. breast implant).</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>3. Epidemiology</strong></h2><ul><li><strong>Worldwide zoonosis</strong>; most common zoonotic infection globally.</li><li><strong>Endemic regions</strong>: Mediterranean basin, Middle East, Africa, Latin America, Central and South Asia.</li><li>UK: ~10 imported cases per year.</li><li>Important occupational hazard: abattoir workers, vets, farmers, meat inspectors, lab staff.</li><li>Human-to-human: rare (sexual, congenital, breast milk, transplant).</li><li><strong>Ingestion</strong>: unpasteurised dairy (milk, cheese) &gt; pasteurisation. </li><li><strong>Direct contact</strong>: animal blood, tissues, aborted products &gt; eliminated by animal vaccination).</li><li><strong>Inhalation</strong>: aerosols on farms, in labs &gt; PPE</li><li>Rare human-to-human.</li><li>Worry re: bioterrorism</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>5. Pathogenesis</strong></h2><ul><li>Enters via mucosa/skin → regional lymph nodes → bloodstream → reticuloendothelial organs.</li><li>Intracellular survival: inhibits apoptosis, suppresses Th1/TNF-α responses.</li><li><strong>Virulence factors</strong>:<ul><li>Smooth LPS (resists complement killing).</li><li>VirB type-IV secretion system (T4SS).</li><li>BvrR/BvrS two-component system.</li><li>Cyclic β-1,2 glucans.</li><li>Superoxide dismutase and urease (acid survival).</li></ul></li><li>Forms granulomas in liver, spleen, marrow.</li><li>Persistence in granulomas → relapsing or chronic disease.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>6. Laboratory Diagnosis</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Safety</strong></h3><ul><li><strong>Hazard Group 3</strong>. Highly infectious (10–100 organisms enough).</li><li>Commonest lab-acquired infection. Work in BSL-3. Notify lab when suspected.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Specimens</strong></h3><ul><li>Blood cultures (yield 15–70%).</li><li>Bone marrow: <strong>gold standard</strong></li><li>Other: Tissue, synovial fluid, CSF</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Culture</strong></h3><ul><li>Slow-growing: 2–3 days up to 8 weeks (usually positive 7–21 days).</li><li>Small convex non-haemolytic colonies.</li><li>Chocolate agar, blood agar, Brucella broth.</li><li>MALDI-TOF can identify (under BSL-3).</li><li>Microscopy: Gram-negative coccobacilli, faint staining.</li><li>Biochemical tests:  Oxidase +, catalase +, urease + (rapid).</li><li>Slide agglutination with specific antisera.</li><li>Molecular : PCR assays increasingly used (esp. for focal disease, FFPE tissue).</li><li>Serology</li><li><strong>SAT (Standard tube agglutination test)</strong>: titre ≥1:160 significant.</li><li><strong>Rose Bengal test</strong>: screening.</li><li>ELISA (IgM vs IgG).</li><li>Coombs anti-Brucella: useful in chronic disease.</li><li><em>B. canis</em> requires separate serology.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>7. Clinical Features</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Incubation</strong></h3><ul><li>Typically 2–4 weeks (range: 5 days – 6 months).</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>General symptoms</strong></h3><ul><li>“Great imitator”: non-specific systemic illness.</li><li><strong>Undulant fever</strong>, night sweats (malodorous, “wet hay” smell), malaise, anorexia, arthralgia, myalgia, headache, weight loss.</li><li>Lymphadenopathy, hepatosplenomegaly.</li><li>Anaemia, leukopenia, thrombocytopenia possible.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Focal disease (~30%)</strong></h3><ul><li><strong>Osteoarticular</strong> (most common, up to 50%): sacroiliitis, spondylitis, peripheral arthritis.</li><li><strong>Genitourinary</strong>: epididymo-orchitis; female pelvic infections, abortion, infertility.</li><li><strong>Hepatic</strong>: hepatitis, granulomas, abscesses.</li><li><strong>Cardiac</strong>: endocarditis (&lt;2% but major cause of death), myocarditis, pericarditis, mycotic aneurysms.</li><li><strong>Neurological (10%)</strong>: neurobrucellosis – meningitis, meningoencephalitis, myelitis, radiculopathy, cranial nerve palsy.</li><li><strong>Respiratory</strong> (rare): bronchitis, pneumonia, pleural effusion, TB-like miliary pattern.</li><li><strong>Ocular</strong>: uveitis, optic neuritis.</li><li><strong>Cutaneous</strong>: varied, vasculitic, psoriasiform lesions.</li><li><strong>Pregnancy</strong>: ↑ risk of miscarriage, preterm labour, congenital infection → avoid breastfeeding.</li><li><strong>Children</strong>: abdominal pain, arthritis more common. Chronicity rare.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>8. Treatment</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Principles</strong></h3><ul><li>Always <strong>combination therapy</strong> for ≥6 weeks.</li><li>Aim: intracellular penetration, relapse prevention.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Uncomplicated brucellosis (WHO first-line)</strong></h3><ul><li><strong>Doxycycline 100 mg PO BD × 6 weeks + Rifampicin 600–900 mg OD × 6 weeks</strong>.</li><li>Alternative: Doxycycline × 6 weeks + Streptomycin (or gentamicin 5mg/kg) 1 g IM daily × 2–3 weeks.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Complicated</strong></h3><ul><li><strong>Spondylitis/osteomyelitis</strong>: prolonged (3–6 months).</li><li><strong>Neurobrucellosis</strong>: Doxycycline + Rifampicin + Ceftriaxone (IV 1 month) for 4–6 months. Continue until CSF normalises.</li><li><strong>Endocarditis</strong>: Doxycycline + Rifampicin + Aminoglycoside; surgery often needed.</li><li><strong>Pregnancy</strong>: Rifampicin monotherapy (TMP-SMX if appropriate, but avoid near term).</li><li><strong>Children &lt;8 years</strong>: Rifampicin + TMP-SMX.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Special note</strong></h3><ul><li>Vaccine strain <em>B. abortus</em> RB51 is <strong>rifampicin-resistant</strong> → use doxycycline + TMP-SMX.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Relapse</strong></h3><ul><li>Occurs in 5–15%. Risk: poor compliance, late diagnosis, focal disease. Retreatment with prolonged combos.</li></ul><h1 class="text-2xl font-bold mt-8 mb-4"><strong>Key Exam Pearls</strong></h1><ul><li><strong>Bone marrow culture &gt; blood culture</strong> for sensitivity.</li><li><strong>B. melitensis</strong> = most pathogenic.</li><li><strong>Combination therapy (Doxy + Rifampicin)</strong> always.</li><li><strong>Endocarditis = main cause of mortality</strong>.</li><li><strong>Neurobrucellosis → triple therapy + prolonged duration</strong>.</li><li><strong>Lab hazard – inform lab</strong></li></ul>
</div>